Publication at Central Library of Charles University, Faculty of Medicine in Hradec Králové |
2004
Abstract
We got our experience with imatinib on more than two-year monitoring 34 patients in chronic phase of chronic myeloid leukemia. Complete hematologic response (97%), complete cytogenetic response (48%) was observed.
Competitive RT-PCR and real-time RT-PCR LightCycler were found useful to monitor patients with CML on imatinib therapy.